Stay updated on Comparison of Risankizumab vs Methotrexate in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Comparison of Risankizumab vs Methotrexate in Psoriasis Clinical Trial page.

Latest updates to the Comparison of Risankizumab vs Methotrexate in Psoriasis Clinical Trial page
- Check2 days agoChange DetectedThe ClinicalTrials.gov page still displays a 403 Forbidden error. Its footer revision changes from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check9 days agoChange DetectedA site-wide NIH announcement was added, advising visitors about updated terminology during the agency’s transition.SummaryDifference1%

- Check16 days agoChange DetectedThe footer revision marker changes from v3.7.1 to v3.7.2. The page still shows a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedThe footer now identifies the ClinicalTrials.gov site revision as v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check37 days agoChange DetectedRemoved the 403 Forbidden content from the study page, allowing the study details to load and be viewed by users.SummaryDifference0.5%

- Check44 days agoChange DetectedThe study page now presents a 403 Forbidden error page instead of the study details, showing the site’s standard layout with a 403 message and a Home button. This indicates access to the study record is blocked or the page failed to load.SummaryDifference17%

Stay in the know with updates to Comparison of Risankizumab vs Methotrexate in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Comparison of Risankizumab vs Methotrexate in Psoriasis Clinical Trial page.